Small-Molecule-Based Nanoassemblies as Inducible Nanoprobes for Monitoring Dynamic Molecular Interactions Inside Live Cells** by Lee, Sangkyu et al.
Biological Nanoparticles
DOI: 10.1002/anie.201101467
Small-Molecule-Based Nanoassemblies as Inducible Nanoprobes for
Monitoring Dynamic Molecular Interactions Inside Live Cells**
Sangkyu Lee, Kyoung Hu Lee, Jae-Seok Ha, Seung-Goo Lee, and Tae K. Kim*
Monitoring dynamic protein–protein interactions is a funda-
mental step to elucidate a variety of signaling processes inside
cells. Identifying the target proteins of bioactive small
molecules is critical to understanding their intracellular
action mechanisms. Although several technologies to probe
these protein–protein and small-molecule–protein interac-
tions were developed,
[1] they suffer from diverse intrinsic
problems including high background noise, false positive/
negative modes, limited sensitivity and dynamic range, and
indirect or delayed readouts. In addition, the use of an
artificial milieu, such as in vitro binding conditions or non-
mammalian cells, has often led to erroneous experimental
outputs.
[2] Recently, various types of imaging-based nano-
technologies have emerged to address these limitations.
[3]
Despite their enormous potential as nanosensors, application
of artificially synthesized nanoparticles to probing molecular
interactions inside living mammalian cells is somewhat
limited by several factors including the prerequisite of
efficient and nondisruptive introduction of nanoparticles
throughout the cells.
[3c,4]
Herein, we present a novel phenotypic readout called
InCell SMART-i (intracellular supramolecular assembly
readout trap for interactions) to directly visualize dynamic
molecular interactions within living mammalian cells. Instead
of intracellular delivery of artificially synthesized nanoparti-
cles, we employed a strategy to induce the formation of
biological nanoparticles by genetic instructions inside living
cells. Many organisms have been known to assemble intra-
cellular nanoparticles such as ferritin complexes. It was
reported that highly uniform nanoparticles can be assembled
by ferritin polymerization under in vitro conditions, and its
polymeric state was still retained when expressed in mamma-
lian cells and in vivo.
[5] In InCell SMART-i (Scheme 1),
genetically engineered ferritin (FT) is used to form nano-
particles (NPs) displaying specific bait (B) or prey (P)
molecules inside cells. Inside living cells, the bait molecules
on FT-derived nanoparticles (FT-NPs) interact with their
target prey molecules. These specific molecular interactions
induce the interconnected assembly of FT-NPs into nano-
clusters.
[6] Consistent with these specific molecular interac-
tions, bait and prey molecules on FT-NPs are co-translocated
from the cytoplasm to the newly assembled nanoclusters.
Fusion of afluorescent probe (F) to the bait or prey molecules
enables the facile detection of these phenotypic alterations by
fluorescent microscopy. These nanocluster formation pro-
cesses may be cooperative because of the multivalent proper-
ties of FT-NPs.
[5] In this setting, physical interactions between
the bait and prey molecules can be effectively visualized in
individual living cells.
To verify this idea, we first examined whether InCell
SMART-i could detect specific molecular interactions inside
living cells by exploiting rapamycin, a cell-permeable immu-
nosuppressant drug interacting with the FK506 binding
protein (FKBP) and with the FKBP-rapamycin binding
Scheme 1. InCell SMART-i. Genetically encoded nanoparticles (NPs)
derived from ferritin (FT) are labeled with fluorescent probes (F) for
facile detection with fluorescent microscopy. FT-NPs directly or indi-
rectly (as represented in Figure 4c, for instance) display specific bait
(B) or prey (P) molecules inside living cells. Specific B–P interactions
induce the interconnected assembly of FP-NPs into nanoclusters
which are detected as discrete punctated dots of fluorescence. Using a
small-molecule switch, such as rapamycin as an inducer of FKBP-FRB
heterodimerization, nanocluster formation can be specifically con-
trolled as shown in Figure 4c.
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[7] Based on this FKBP-
FRB heterodimerization, rapamycin has been utilized to
rapidly control specific molecular interactions inside cells.
[8]
To visualize the formation of nanoclusters within cells,
monomeric red (mRFP) and enhanced green (EGFP) fluo-
rescent proteins were fused to the FKBP and FRB, respec-
tively (Figure 1a). HeLa cells were co-transfected with
expression plasmids for FKBP-mRFP and FRB-EGFP
fused to the N terminus of ferritin (FT). Before induction,
nanocluster formation was barely detectable and FT-fusion
proteins were mostly dispersed throughout the cytoplasm
(Figure 1b). In contrast, addition of rapamycin induced the
heterodimerization of FKBP and FRB displayed on FT-NPs,
rapidly driving the assembly of discrete punctated dots of
fluorescence within seconds inside cells (Figure 1b; see also
Movie S1 in the Supporting Information). Consistent with
FKBP-FRB interactions through rapamycin, we observed the
rapamycin-induced co-translocation of FKBP-mRFP-FT and
FRB-EGFP-FT from the dispersed cytoplasm to these newly
detected punctated fluorescent dots of nanoclusters. These
imaging data indicate that interactions of rapamycin with
FKBP and FRB induced the assembly of nanoclusters in
concomitant with their co-localization onto the nanoclusters
in InCell SMART-i.
The specificity of nanocluster formation by interactions of
rapamycin with FKBP and FRB was further assessed by a
series of following experiments. First, nanoclusters were
assembled by rapamycin in the presence of both FKBP-
mRFP-FTand FRB-EGFP-FT, but neither in the presence of
FKBP-mRFP-FT norin the presenceofFRB-EGFP-FTalone
(Figure S1 in the Supporting Information). Second, other
fluorescent proteins including the enhanced yellow (EYFP)
and cyan (ECFP) fluorescent proteins also showed rapamy-
cin-dependent nanocluster formation through heterodimeri-
zation of FKBP and FRB on FT-NPs inside cells (Figure S2 in
the Supporting Information). Third, FK506, which binds to
FKBP but not to FRB, blocked this nanocluster formation as
a specific competitor for rapamycin interactions with FKBP
and FRB (Figure 2).
[7] All of these results support the
specificity of the InCell SMART-i technology for molecular
interactions inside living cells. Furthermore, the nanocluster
formation did not elicit any detectable toxic effects on the cell
viability even after long-term (48 h) incubation (Figure S3 in
the Supporting Information).
We next examined the quantitative dynamics of nano-
cluster formation inside living cells expressing FKBP-mRFP-
FT and FRB-EGFP-FT. Nanocluster formation was quanti-
tatively analyzed by the number of assembled nanoclusters
with sizes over 0.2 mm
2 and circularities between 0.5–1.0.
Nanocluster formation was initiated as a rapid response to
rapamycin induction on a timescale of seconds and became
almost saturated within 3–5 min (Figure 3a; see also
Movie S1 in the Supporting Information). This rapamycin-
dependent nanocluster formation is specific because it was
not observed in the absence of FKBP or FRB (Figure 3a).
The assembly of nanoclusters was augmented with increasing
Figure 1. InCell SMART-i for visualizing small-molecule–protein inter-
actions inside living cells. a) InCell SMART-i detecting interactions of
rapamycin with FKBP and FRB using ferritin-derived nanoparticles (FT-
NPs). b) Time-lapse images of nanocluster formation. Scale
bar=20 mm.
Figure 2. Specific inhibition of nanocluster formation by a competitive
inhibitor. HeLa cells were co-transfected with the expression plasmids
as indicated. Rapamycin (250 nm) with and without FK506 (25 mm).
The images were captured before (0 min) and after (10 min) treatment
with rapamycin/FK506. Scale bar=20 mm.
Figure 3. Quantitative analysis of nanocluster formation. a) Temporal
analysis of nanocluster formation by FKBP–rapamycin–FRB interac-
tions (rectangles, FKBP; triangles, FRB; circles, FKBP+FRB). b) Dose-
dependent nanocluster formation inside living cells.
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100 nm (Figure 3b). Interestingly, nanocluster formation was
dynamically visualized at the subcellular level throughout the
cytoplasm on a timescale of seconds (Figure S4 and Movie S1
in the Supporting Information). Notably, high levels of
induction in nanocluster formation with high signal-to-noise
ratios and distinct phenotypic alterations may facilitate the
quantitative analysis of dynamic molecular interactions
within live cells (Figure 3; see also Figures 1 and 2). These
results suggest that InCell SMART-i can be used for
monitoring dynamics of specific interactions of a small
molecule with its target protein(s) inside living cells.
Furthermore, we evaluated the feasibility of InCell
SMART-i for probing protein–protein interactions in the
intracellular signaling processes using the NF-kB pathway.
[9]
Members of the NF-kB family (e.g., RelA/p65) are seques-
tered within the cytoplasm by the IkB family member (e.g.,
IkBa). Various stimuli, including TNF-a, induce the phos-
phorylation of IkBa by IKKb. To detect RelA-IkBa inter-
actions in cells, we tested two related formats for monitoring
nanocluster formation that are inducible in a rapamycin-
dependent manner, extended from our results in Figure 1. As
depicted in Figure 4a,c, IkBa or/and RelA were directly or
indirectly displayed on FT-NPs using rapamycin-dependent
heterodimerization of FKBP and FRB in HeLa cells.
Consistent with RelA-IkBa interactions, rapamycin elicited
a bridging function to induce the interconnected assembly of
nanoclusters in live cells (Figure 4b,d). Consistently, addition
of rapamycin rapidly induced co-translocation of RelA/IkBa-
fusion proteins from the cytoplasm to the newly assembled
nanoclusters. These results suggest that rapamycin may be
useful as a small-molecule switch to inducibly visualize
nanocluster formation for probing intracellular molecular
interactions in InCell SMART-i. This inducible system with
an immediate readout on a timescale of seconds may allow
reliable detection for molecular interactions by eliminating
nonspecific interactions or aggregates within living cells.
We also examined whether InCell SMART-i can be used
to probe signal-dependent interactions of a kinase with its
substrate, which are mostly weak and transient, by monitoring
TNF-a-induced interactions of IKKb with IkBa. Both IKKb
and IkBa were indirectly displayed on FT-NPs using rapa-
mycin-dependent heterodimerization of FKBP and FRB in
HeLa cells (Figure 4e). Prior to TNF-a stimulation, forma-
tion of nanoclusters was barely detectable. Treatment with
rapamycin along with TNF-a inducibly visualized nanocluster
formation (Figure 4 f), reflecting signal-dependent interac-
tions of IKKb kinase with its substrate IkBa inside live cells.
Thus, this sensitive system allowed detection of specific and
transient protein–protein interactions in response to external
stimuli, further emphasizing the specificity of the InCell
SMART-i technology inside live cells.
Next, to test whether InCell SMART-i can be used to
probe molecular interactions in other intracellular compart-
ments such as nucleus or plasma membranes, we targeted FT-
NPs to the nucleus or plasma membranes by using the nuclear
Figure 4. InCell SMART-i for visualizing protein–protein interactions inside living cells. a,c) InCell SMART-i detecting IkBa-RelA interactions using
ferritin-derived nanoparticles (FT-NPs). b,d) Specific nanocluster formation by IkBa-RelA interactions. e) InCell SMART-i detecting TNF-a-
dependent IkBa-IKKb interactions using ferritin-derived nanoparticles (FT-NPs). b,d,f) HeLa cells co-transfected with the expression plasmids as
indicated were treated with DMSO or rapamycin (500 nm for b,d; 50 nm for f). The images were captured before (0 min) and after (10 min)
rapamycin treatment. f) Specific nanocluster formation by IkBa-IKKb interactions in response to TNF-a (10 ngmL
1). Scale bars=20 mm.
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domain of Akt which is known to bind phosphatidylinositol
(3,4,5)-triphosphate (PIP3) in the plasma membrane.
[10] We
inserted NLS into FKBP-ECFP-FTand FRB-mRFP-FT, and
the PH domain into FKBP-mRFP-FT and FRB-EGFP-FT
(Figures S5a and S6 in the Supporting Information). Consis-
tent with cytosolic interactions as demonstrated in Figure 1,
addition of rapamycin rapidly induced the formation of
nanoclusters in the nucleus or plasma membranes in con-
comitant with co-translocation of FKBP and FRB from the
nucleus or plasma membranes to the newly assembled
nanoclusters.
We further examined the feasibility of InCell SMART-i in
visualizing molecular interactions inside the nucleus by
exploiting protein–protein interactions of p53 with MDM2
in the nucleus (Figure S5b in the Supporting Information).
[11]
Following the scheme dipicted in Figure 4c, p53 and MDM2
were indirectly displayed on nuclear-localized FT-NPs using
rapamycin-dependent heterodimerization of FKBP and FRB.
Upon treatment with rapamycin, nanoclusters were rapidly
assembled by specific interactions of p53 with MDM2 inside
the nucleus, demonstrating the spatial resolution of InCell
SMART-i for intracellular molecular interactions (see also
Figure S4 and Movie S1 in the Supporting Information).
Detection of the interactions ofa bioactive small molecule
with its target protein(s) is essential for understanding its
intracellular action mechanisms as well as its therapeutic and/
or deleterious effects.
[1,12] We determined whether InCell
SMART-i can detect the intracellular target of a small drug
molecule inside living cells by exploiting methotrexate
(MTX), an anti-cancer drug interacting with its therapeutic
target protein of dihydrofolate reductase (DHFR, Figure S7
in the Supporting Information).
[13] HeLa cells were co-trans-
fected with expression plasmids for FKBP, FRB, and DHFR
fused to mRFP-FT, displaying FKBP, FRB, and DHFR on FT-
NPs within cells. As demonstrated in Figure 1, rapamycin
rapidly induced formation of nanoclusters. Under these
conditions, we observed specific recruitment of fluores-
cence-labeled MTX (BODIPY FL-MTX) onto assembled
nanoclusters (Figure S7 in the Supporting Information). In
contrast, this recruitment of BODIPY FL-MTX was not
observed in nanoclusters displaying no DHFR. These results
suggest that InCell SMART-i will be useful for identifying
targets of small-molecule modulators from phenotypic
screening for development of molecular probes by biochem-
ical approaches.
[1,12]
In summary, we have developed a novel and effective
readout for specific molecular interactions inside living cells
by monitoring the induced assembly of nanoclusters. InCell
SMART-i may offer several advantages compared to tradi-
tional technologies. First, it probes biomolecular interactions
in a physiologically and pharmacologically relevant context,
and thereby greatly diminishes misleading outcomes pro-
duced by artificial experimental settings.
[1–2] Second, InCell
SMART-i directly translates physical interactions into clear
readout signals, unlike indirect readout methods that rely on
complex gene expression or biological phenotypic profiles.
[1]
Third, InCell SMART-i is amenable to dynamic, single-cell
analysis of interactions. Fourth, InCell SMART-i is simpler
and easier to perform relative to the artificially synthesized
nanoparticles, which face practical issues such as facile
intracellular delivery,
[3c,4] because of the use of biologically
self-assembled ferritin complexes inside cells. Fifth, rapid
detection systems are feasible because high signal-to-noise
ratios are observed and inducible by small molecules. There-
fore, InCell SMART-i may be exploited in systematic screen-
ing of diverse molecular interactions inside living cells, as it
efficiently eliminates intrinsic false positive/negative modes
or error-prone deviations. Furthermore, InCell SMART-i
with distinct phenotypic readouts may complement some
limitations of readouts based on fluorescence intensities for
probing molecular interactions such as fluorescence reso-
nance energy transfer (FRET) or bimolecular fluorescence
complementation (BiFC), the shortcomings of which are
limited sensitivity and dynamic range or long maturation
times of fluorophores, respectively.
[14] With these great
advantages, our current efforts include genome-wide inter-
action screens for small-molecule target identification and the
systematic analysis of signal transduction networks.
In conclusion, InCell SMART-i will be useful for probing
dynamic molecular interactions inside living cells with its
technological versatility. Detailed molecular mechanisms
underlying supramolecular assembly of nanoclusters inside
cells remain to be determined, although similar types of
nanoassemblies were also observed in vitro.
[6] In addition, the
use of super-resolution microscopy and other technologies for
small fluorescent tags and small-molecule dimerizers might
further facilitate high-resolution imaging of dynamic molec-
ular interactions and effective use of InCell SMART-i.
[3a,c]
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